SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CMPS

COMPASS Pathways plc (NASDAQ:CMPS)

GB · Delayed Price · Currency is USD
Healthcare · Biotechnology
$8.05-$0.60 (-6.94%)
 
Market cap
$1.14B
Insider Score
Health Score
Analyst consensus
Listed since
Sep 18, 2020
Market Cap$1.14B+55.4%
Revenue (ttm)$0
Net Income-$266.30M-12.2%
EPS-$4.44-63.2%
Shares Out141.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,089,163
Open$8.32
Previous Close$8.65
Day's Range$7.82 - $8.43
52-Week Range$4.88 - $15.87
Beta2.41
AnalystsBuy
Price Target$20.17(+150.56%)
Earnings DateMar 23, 2027

About CMPS

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Address
33 Broadwick Street, London, CH, W1F 0DQ, GB
Market Cap
1.14 billion
Employees
156
Industrial Classification
Biotechnology

Analyst consensus

Moderate Buy
2 Buy1 Hold0 SellAvg target $18.90 (+134.8%)

3 firms rating CMPS in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From CMPS’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-6.94%
5 Days
-8.00%
1 Month
-30.78%
6 Months
-31.84%
1 Year
+55.41%

$CMPS stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CMPS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CMPS's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CMPS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

CMPS Revenue by Segment

$99.82MTotal
Single Operating Segment$56.44M56.54%
Fair value change of warrant liabilities$40.78M40.85%
Benefit from R&D tax credit$2.05M2.05%
Other income$556.00K0.56%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New CMPS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CMPS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CMPS

ARKGARK Genomic Revolution ETF$48.56M
IBBiShares Biotechnology ETF$7.09M
PSILAdvisorShares Psychedelics ETF$3.98M
SBIOALPS Medical Breakthroughs ETF$1.36M
TMSLT. Rowe Price Small-Mid Cap ETF$1.25M
GWXState Street SPDR S&P International Small Cap ETF$874.63K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CMPS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
72

News check: FDA NDA submission for COMP360 and positive catalyst expectations for 2027 approval outweigh valuation opinion pieces.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

PSILAdvisorShares Psychedelics ETF10.56%
ARKGARK Genomic Revolution ETF2.64%
AADRAdvisorShares Dorsey Wright1.44%
SURISimplify Propel Opportunities ETF1.09%
SBIOALPS Medical Breakthroughs ETF0.83%
HTECROBO Global Healthcare Technology and Innovation ETF0.73%
BBCVirtus Biotech Clinical Trials ETF0.57%
TDNAT. Rowe Price Biotech ETF0.37%
ESIMEventide International ETF0.15%
GWXState Street SPDR S&P International Small Cap ETF0.10%
IBBQInvesco Nasdaq Biotechnology ETF0.08%
IBBiShares Biotechnology ETF0.07%

Weight is the stock’s share of each fund’s holdings.